DEVELOPMENTAL FUNDS ? ABSTRACT Developmental Funds at KCI provide an important and essential source of funds in support of the Cancer Center?s investment in strategic initiatives. These initiatives are formalized through extensive planning and evaluation processes. During the past funding period, CCSG Developmental Funds were used in two key areas; 1) the recruitment of a key investigator in a Program leadership role, and 2) support of strategic pilot projects. CCSG funds were significantly augmented by institutional support to further recruitment efforts and provide funds for pilot projects aligned with KCI?s strategic priorities. Specifically, during the current grant cycle (12/1/2015 to 11/30/2019), $214,813 of CCSG Developmental Funds was augmented by an additional $14.8 million of institutional support to provide valuable support for 51 pilot projects consistent with the strategic vision of KCI and the recruitment of 36 new faculty, including 11 early stage investigators. The completed pilot projects have resulted in a five-fold return on investment measured by success in obtaining peer reviewed extramural funding. Additionally, new faculty level scientists have published 226 peer reviewed articles, secured 59 grant awards, and activated 129 clinical trials since their arrival. CCSG Developmental Funds in the amount of $55,550 are requested to fund pilot projects in the five areas of the Cancer Center?s focused future development. CCSG Developmental Funds, invested in pilot projects and augmented with institutional funding, have successfully driven innovative research and have led to extramurally funded projects over the course of the current grant cycle. This trend is expected to continue into the years to come, as KCI pursues the goals established in the strategic plan and engages with community partners to develop innovative projects that address the specific needs of the catchment area.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-39
Application #
10088981
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-08
Project End
2025-11-30
Budget Start
2020-12-15
Budget End
2021-11-30
Support Year
39
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Herroon, Mackenzie K; Rajagurubandara, Erandi; Diedrich, Jonathan D et al. (2018) Adipocyte-activated oxidative and ER stress pathways promote tumor survival in bone via upregulation of Heme Oxygenase 1 and Survivin. Sci Rep 8:40
Colacino, Justin A; Azizi, Ebrahim; Brooks, Michael D et al. (2018) Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling. Stem Cell Reports 10:1596-1609
Blocker, Stephanie J; Shields, Anthony F (2018) Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery. Mol Imaging Biol 20:340-351
Guastella, Anthony R; Michelhaugh, Sharon K; Klinger, Neil V et al. (2018) Investigation of the aryl hydrocarbon receptor and the intrinsic tumoral component of the kynurenine pathway of tryptophan metabolism in primary brain tumors. J Neurooncol 139:239-249
Li, Feng; Wang, Yongli; Li, Dapeng et al. (2018) Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opin Drug Discov 13:643-660
Ramseyer, Vanesa D; Kimler, Victoria A; Granneman, James G (2018) Vacuolar protein sorting 13C is a novel lipid droplet protein that inhibits lipolysis in brown adipocytes. Mol Metab 7:57-70
Healy, Mark A; Morris, Arden M; Abrahamse, Paul et al. (2018) The accuracy of chemotherapy ascertainment among colorectal cancer patients in the surveillance, epidemiology, and end results registry program. BMC Cancer 18:481
Lacher, Sarah E; Alazizi, Adnan; Wang, Xuting et al. (2018) A hypermorphic antioxidant response element is associated with increased MS4A6A expression and Alzheimer's disease. Redox Biol 14:686-693
Alsaab, Hashem O; Sau, Samaresh; Alzhrani, Rami M et al. (2018) Tumor hypoxia directed multimodal nanotherapy for overcoming drug resistance in renal cell carcinoma and reprogramming macrophages. Biomaterials 183:280-294
Chammaa, May; Malysa, Agnes; Redondo, Carlos et al. (2018) RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer. J Cell Physiol 233:9548-9562

Showing the most recent 10 out of 826 publications